Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that it has finalized... The post Medicenna Announces the Finalization of the Terms of its Public Offering of Securities appeared first on Montreal Gazette .

Original source: Montreal Gazette